Pressemitteilungen Idorsia Ltd

Aktien

A2DTEB

CH0363463438

IDIA

Realtime-Estimate Cboe Europe Andere Börsenplätze 09:21:41 02.05.2024			% 5 Tage	% 1. Jan.
1,904 ^CHF	+5,19 %		-3,65 %	-8,85 %

08:44	Morning Briefing - Markt Schweiz	AW
01.05.	Idorsia erhöht Gegenleistung für Anleihengläubiger	AW

Pressemitteilungen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

GNW-Adhoc: Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond	01.05.	DP
Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond	01.05.	GL
GNW-Adhoc: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension	26.04.	DP
JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension	26.04.	GL
GNW-Adhoc: Idorsia publishes an invitation to a bondholder meeting	23.04.	DP
Idorsia publishes an invitation to a bondholder meeting	23.04.	GL
GNW-Adhoc: Idorsia publishes a Financial Status required for an upcoming bondholder meeting	17.04.	DP
Idorsia publishes a Financial Status required for an upcoming bondholder meeting	17.04.	GL
GNW-Adhoc: Idorsia takes steps to address short-term liquidity needs	11.04.	DP
Idorsia takes steps to address short-term liquidity needs	11.04.	GL
GNW-Adhoc: Idorsia thanks Guy Braunstein for his years of service as he retires	22.03.	DP
Idorsia thanks Guy Braunstein for his years of service as he retires	22.03.	GL
GNW-Adhoc: US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) - the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives	20.03.	DP
US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives	20.03.	GL
GNW-Adhoc: Idorsia and Viatris successfully close the transaction for the global research and development collaboration	18.03.	DP
Idorsia and Viatris successfully close the transaction for the global research and development collaboration	18.03.	GL
GNW-Adhoc: Idorsia and Viatris enter into a significant global research and development collaboration	28.02.	DP
Idorsia and Viatris enter into a significant global research and development collaboration	28.02.	GL
GNW-Adhoc: Idorsia presents at the J.P. Morgan Healthcare Conference - Adapting Idorsia for sustainable value creation	10.01.	DP
Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation	10.01.	GL

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

Idorsia Ltd: Ein Jahr mit Licht und Schatten

Am 10. Mai 2023 um 10:35 Uhr